

AVI BIOPHARMA INC  
Form 8-K  
March 14, 2007

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of Earliest Event Reported): **January 8, 2007**

**AVI BioPharma, Inc.**

(Exact name of Company as specified in its charter)

**Oregon**  
(State or other  
jurisdiction of  
incorporation)

**0-22613**  
(Commission File No.)

**93-0797222**  
(I.R.S. Employer  
Identification No.)

**One S.W. Columbia, Suite 1105  
Portland, OR 97258**  
(Address of principal executive offices)

**(503) 227-0554**  
Registrant's telephone number, including area code

**Not Applicable**  
(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))



**Section 1**                      **Registrant's Business and Operations**

**Item 1.01.**                      **Entry into a Material Definitive Agreement**

On January 8, 2007, AVI BioPharma, Inc. (Nasdaq: AVII) ( "AVI" ) entered into a cross-license agreement with Eleos, Inc. to identify and develop drugs utilizing certain proprietary antisense technology relating to the regulation of certain proteins.

Under the terms of the license agreement, each party granted the other rights with respect to certain proprietary technology within defined fields of use. The agreement also contains customary provisions regarding indemnification and confidentiality and payment of royalties upon reaching certain milestones. Eleos paid \$500,000 to AVI upon execution of the license agreement.

**Section 7**                      **Regulation FD**

**Item 7.01**                      **Regulation FD Disclosure**

The information set forth above is incorporated by reference herein.

**Section 8**                      **Other Events**

**Item 8.01**                      **Other Events**

The information set forth above is incorporated by reference herein.

\*\*\*

**SIGNATURES**

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Portland, State of Oregon, on March 14, 2007.

AVI BioPharma, Inc.

By:                              /s/ ALAN P. TIMMINS

Alan P. Timmins  
*President and Chief Operating Officer*  
*(Principal Operating Officer)*